Dermatology

Title of studyPosted Recruitment end date Further info and contact
A Phase 3, Randomized, Double-Blind, Placebo-Controlled Parallel Study to Evaluate the Efficacy and Safety of Enpatoran in Participants with Active Cutaneous Manifestations of Lupus Erythematosus With or Without Systemic Disease Receiving Standard of Care30 Sep 2026 Frances Burns
03 9076 8592
dermtrials@alfred.org.au
A multicenter, randomized, double-blind, placebo controlled, dose-range Phase IIb study to assess the efficacy and safety of GIA632 in participants with moderate to severe cutaneous lichen planus, followed by an optional open-label extension period23 Sep 2026 Frances Burns
03 9076 8592
dermtrials@alfred.org.au
SkinNomics: A research study investigating microbiome alterations in inflammatory oral mucosal disease24 Aug 2026 Frances Burns
03 9076 8592
dermtrials@alfred.org.au
A multicenter, randomized, double-blind, placebo controlled, dose ranging Phase IIb study to assess the efficacy and safety of GIA632 in adult participants with non-segmental vitiligo followed by an extension period17 Apr 2026 Frances Burns
03 9076 8592
dermtrials@alfred.org.au
Study to evaluate Safety, Efficacy and Immunogenicity of Acne mRNA
Vaccine in Adults with Moderate to Severe Acne		17 Apr 2026 Frances Burns
03 9076 8592
dermtrials@alfred.org.au
A randomized, double-blind, placebo-controlled, dose ranging Phase 2 study of brivekimig followed by a maintenance period in participants with moderate to severe hidradenitis suppurativa28 Nov 2025 Frances Burns
03 9076 8592
dermtrials@alfred.org.au
Skin Microbiome Study 23 May 2025   Frances Burns
03 9076 8592
dermtrials@alfred.org.au
Antigen Triggers in Inflammatory Skin-disease 16 May 2025   Frances Burns
03 9076 8592
dermtrials@alfred.org.au